Axovant Sciences (AXON) Reports Q4 Loss of $0.53/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Axovant Sciences Announces Fiscal Year-End Financial Results and Corporate Updates
June 13, 2017 7:00 AM EDT
BASEL, Switzerland, June 13, 2017 /PRNewswire/ --Â Axovant Sciences (NYSE:Â AXON), today reported financial results for the fourth fiscal quarter and full fiscal year ended March 31, 2017, as well as general business updates.
Key Highlights
Strong balance sheet with $212.6 million of cash as of March 31, 2017 supports Company's current development plans; does not include net proceeds of $134.2 million from the Company's recent follow-on offering Patient recruitment complete for HEADWAY-DLB clinical study Initiation of RVT-104... More